ReviewNeuro-oncology2014
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
Open access · bronzeAbstract readReview
In one paragraph
Review in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 8 pooled it
12.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 8 syntheses or guidelines pooled it, 260 citations in OpenAlex.
- The concept, intention, and evaluation of the term treatment-refractory meningioma.Journal of neuro-oncology · 2025Pooled it
- Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design.Neuro-oncology · 2025Pooled it
- European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.Neuro-oncology · 2025Guideline
- Meningioma animal models: a systematic review and meta-analysis.Journal of translational medicine · 2023Pooled it
- Efficacy of radiotherapy and stereotactic radiosurgery as adjuvant or salvage treatment in atypical and anaplastic (WHO grade II and III) meningiomas: a systematic review and meta-analysis.Neurosurgical review · 2023Pooled it
- Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data.Neurosurgical review · 2022Pooled it
- EANO guideline on the diagnosis and management of meningiomas.Neuro-oncology · 2021Guideline
- Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review.Cancer biology & therapy · 2020Pooled it
- Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial.Nature medicine · 2026Trial
- Phase 2 Trial of PD-1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma.CNS neuroscience & therapeutics · 2025Trial
- Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With SomaticJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).Neuro-oncology · 2022Trial
- Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.Nature communications · 2022Trial
- Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.Neuro-oncology · 2022Trial
- Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.Neuro-oncology · 2021Trial
- Trial
- Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.Neurology · 2015Trial
- Review
- Targeted therapies in adolescent and young adult patients with central nervous system tumors.Neuro-oncology advances · 2026Review
- Photodynamic therapy using talaporfin sodium for grade 2/3 meningiomas: a preliminary study of safety, feasibility, and clinical outcomes.Journal of neuro-oncology · 2026Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Thomas KaleyDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (T.K.); Department of Radiation Oncology, University of California, San Francisco, San Francisco, California (I.B.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurosurgery, University of California, San Francisco, San Francisco, California (M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (K.P.); Department of Neurology, Northwestern University, Chicago, Illinois (J.R.); Department of Radiation Oncology, Gamma West Cancer Services, Salt Lake City, Utah (L.R.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neuro-Oncology, Cleveland Clinic, Cleveland, Ohio (M.V.); Division of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland (D.W.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/Brigham and Women's Center, Boston, Massachsetts (P.W.).
Igor BaraniDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (T.K.); Department of Radiation Oncology, University of California, San Francisco, San Francisco, California (I.B.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurosurgery, University of California, San Francisco, San Francisco, California (M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (K.P.); Department of Neurology, Northwestern University, Chicago, Illinois (J.R.); Department of Radiation Oncology, Gamma West Cancer Services, Salt Lake City, Utah (L.R.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neuro-Oncology, Cleveland Clinic, Cleveland, Ohio (M.V.); Division of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland (D.W.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/Brigham and Women's Center, Boston, Massachsetts (P.W.).
Marc ChamberlainDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (T.K.); Department of Radiation Oncology, University of California, San Francisco, San Francisco, California (I.B.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurosurgery, University of California, San Francisco, San Francisco, California (M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (K.P.); Department of Neurology, Northwestern University, Chicago, Illinois (J.R.); Department of Radiation Oncology, Gamma West Cancer Services, Salt Lake City, Utah (L.R.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neuro-Oncology, Cleveland Clinic, Cleveland, Ohio (M.V.); Division of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland (D.W.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/Brigham and Women's Center, Boston, Massachsetts (P.W.).
Michael McDermottDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (T.K.); Department of Radiation Oncology, University of California, San Francisco, San Francisco, California (I.B.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurosurgery, University of California, San Francisco, San Francisco, California (M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (K.P.); Department of Neurology, Northwestern University, Chicago, Illinois (J.R.); Department of Radiation Oncology, Gamma West Cancer Services, Salt Lake City, Utah (L.R.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neuro-Oncology, Cleveland Clinic, Cleveland, Ohio (M.V.); Division of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland (D.W.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/Brigham and Women's Center, Boston, Massachsetts (P.W.).
Katherine PanageasDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (T.K.); Department of Radiation Oncology, University of California, San Francisco, San Francisco, California (I.B.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurosurgery, University of California, San Francisco, San Francisco, California (M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (K.P.); Department of Neurology, Northwestern University, Chicago, Illinois (J.R.); Department of Radiation Oncology, Gamma West Cancer Services, Salt Lake City, Utah (L.R.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neuro-Oncology, Cleveland Clinic, Cleveland, Ohio (M.V.); Division of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland (D.W.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/Brigham and Women's Center, Boston, Massachsetts (P.W.).
Jeffrey RaizerDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (T.K.); Department of Radiation Oncology, University of California, San Francisco, San Francisco, California (I.B.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurosurgery, University of California, San Francisco, San Francisco, California (M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (K.P.); Department of Neurology, Northwestern University, Chicago, Illinois (J.R.); Department of Radiation Oncology, Gamma West Cancer Services, Salt Lake City, Utah (L.R.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neuro-Oncology, Cleveland Clinic, Cleveland, Ohio (M.V.); Division of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland (D.W.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/Brigham and Women's Center, Boston, Massachsetts (P.W.).
Leland RogersDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (T.K.); Department of Radiation Oncology, University of California, San Francisco, San Francisco, California (I.B.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurosurgery, University of California, San Francisco, San Francisco, California (M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (K.P.); Department of Neurology, Northwestern University, Chicago, Illinois (J.R.); Department of Radiation Oncology, Gamma West Cancer Services, Salt Lake City, Utah (L.R.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neuro-Oncology, Cleveland Clinic, Cleveland, Ohio (M.V.); Division of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland (D.W.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/Brigham and Women's Center, Boston, Massachsetts (P.W.).
David SchiffDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (T.K.); Department of Radiation Oncology, University of California, San Francisco, San Francisco, California (I.B.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurosurgery, University of California, San Francisco, San Francisco, California (M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (K.P.); Department of Neurology, Northwestern University, Chicago, Illinois (J.R.); Department of Radiation Oncology, Gamma West Cancer Services, Salt Lake City, Utah (L.R.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neuro-Oncology, Cleveland Clinic, Cleveland, Ohio (M.V.); Division of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland (D.W.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/Brigham and Women's Center, Boston, Massachsetts (P.W.).
Michael VogelbaumDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (T.K.); Department of Radiation Oncology, University of California, San Francisco, San Francisco, California (I.B.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurosurgery, University of California, San Francisco, San Francisco, California (M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (K.P.); Department of Neurology, Northwestern University, Chicago, Illinois (J.R.); Department of Radiation Oncology, Gamma West Cancer Services, Salt Lake City, Utah (L.R.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neuro-Oncology, Cleveland Clinic, Cleveland, Ohio (M.V.); Division of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland (D.W.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/Brigham and Women's Center, Boston, Massachsetts (P.W.).
Damien WeberDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (T.K.); Department of Radiation Oncology, University of California, San Francisco, San Francisco, California (I.B.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurosurgery, University of California, San Francisco, San Francisco, California (M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (K.P.); Department of Neurology, Northwestern University, Chicago, Illinois (J.R.); Department of Radiation Oncology, Gamma West Cancer Services, Salt Lake City, Utah (L.R.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neuro-Oncology, Cleveland Clinic, Cleveland, Ohio (M.V.); Division of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland (D.W.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/Brigham and Women's Center, Boston, Massachsetts (P.W.).
Patrick WenDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (T.K.); Department of Radiation Oncology, University of California, San Francisco, San Francisco, California (I.B.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurosurgery, University of California, San Francisco, San Francisco, California (M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (K.P.); Department of Neurology, Northwestern University, Chicago, Illinois (J.R.); Department of Radiation Oncology, Gamma West Cancer Services, Salt Lake City, Utah (L.R.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neuro-Oncology, Cleveland Clinic, Cleveland, Ohio (M.V.); Division of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland (D.W.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/Brigham and Women's Center, Boston, Massachsetts (P.W.).
Memorial Sloan Kettering Cancer Center · USCleveland Clinic · USNorthwestern University · USUniversity of California, San Francisco · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
backgroundThe outcomes of patients with surgery- and radiation-refractory meningiomas treated with medical therapies are poorly defined. Published reports are limited by small patient numbers, selection bias, inclusion of mixed histologic grades and stages of illness, and World Health Organization (WHO) criteria changes. This analysis seeks to define outcome benchmarks for future clinical trial design.
methodsA PubMed literature search was performed for all English language publications on medical therapy for meningioma. Reports were tabulated and analyzed for number of patients, histologic grade, prior therapy, overall survival, progression-free survival (PFS), and radiographic response.
resultsForty-seven publications were identified and divided by histology and prior therapies, including only those that treated patients who were surgery and radiation refractory for further analysis. This included a variety of agents (hydroxyurea, temozolomide, irinotecan, interferon-α, mifepristone, octreotide analogues, megestrol acetate, bevacizumab, imatinib, erlotinib, and gefitinib) from retrospective, pilot, and phase II studies, exploratory arms of other studies, and a single phase III study. The only outcome extractable from all studies was the PFS 6-month rate, and a weighted average was calculated separately for WHO grade I meningioma and combined WHO grade II/III meningioma. For WHO I meningioma, the weighted average PFS-6 was 29% (95% confidence interval [CI]: 20.3%-37.7%). For WHO II/III meningioma, the weighted average PFS-6 was 26% (95% CI: 19.3%-32.7%).
conclusionsThis comprehensive review confirms the poor outcomes of medical therapy for surgery- and radiation-refractory meningioma. We recommend the above PFS-6 benchmarks for future trial design.
Indexed as
BenchmarkingHumansMeningeal NeoplasmsMeningiomaSurvival AnalysisTreatment Outcomeanaplastic meningiomaatypical meningiomachemotherapy meningiomamalignant meningiomameningioma
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.